At a glance
- Originator Eli Lilly and Company
- Class Antineoplastics; Small molecules
- Mechanism of Action Phosphoribosylglycinamide formyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
Most Recent Events
- 01 Feb 1995 No-Development-Reported for Cancer in USA (Unknown route)